Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors
暂无分享,去创建一个
J. Norman | A. Reynolds | Dylan T. Jones | M. Gourlaouen | J. Welti | I. Hart | Jim C Norman | Andrew R Reynolds | Kairbaan M Hodivala-Dilke | Gordon C Tucker | G. Tucker | V. Kostourou | S. Robinson | K. Hodivala-Dilke | Vassiliki Kostourou | Ian R Hart | Alan R Watson | Jonathan C Welti | Rita G Silva | Stephen D Robinson | Georges Da Violante | Morgane Gourlaouen | Mishal Salih | Matt C Jones | Dylan T Jones | Garry Saunders | Françoise Perron-Sierra | R. Silva | Alan R. Watson | F. Perron-Sierra | Mishal Salih | G. Saunders | Rita Silva
[1] J. Rees. Neuro-oncology , 2010, Practical Neurology.
[2] Andrew J. Lindsay,et al. Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.
[3] Kairbaan Hodivala-Dilke,et al. alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. , 2008, Current opinion in cell biology.
[4] L. Ellis,et al. VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.
[5] J. Norman,et al. Endocytic transport of integrins during cell migration and invasion. , 2008, Trends in cell biology.
[6] K. Hodivala-Dilke. avb3 integrin and angiogenesis: a moody integrin in a changing environment , 2008 .
[7] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[8] Daniel L. Gustafson,et al. Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors , 2007 .
[9] J. Kirkwood,et al. Integrins and cancer. , 2007, Oncology.
[10] R. Stupp,et al. Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] T. Mikkelsen,et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[13] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[14] H. Friess,et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer , 2006, BMC Cancer.
[15] J. Hickman,et al. Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells , 2006 .
[16] T. Byzova,et al. Integrin signaling is critical for pathological angiogenesis , 2006, The Journal of experimental medicine.
[17] J. Norman,et al. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. , 2006, Blood.
[18] Gareth Howell,et al. Intrinsic Tyrosine Kinase Activity is Required for Vascular Endothelial Growth Factor Receptor 2 Ubiquitination, Sorting and Degradation in Endothelial Cells , 2006, Traffic.
[19] F. Orsenigo,et al. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments , 2006, The Journal of cell biology.
[20] L. Claesson‐Welsh,et al. VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.
[21] G. Tucker. Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.
[22] Gáspár Jékely,et al. Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. , 2005, Developmental cell.
[23] E. Calabrese. Cancer Biology and Hormesis: Human Tumor Cell Lines Commonly Display Hormetic (Biphasic) Dose Responses , 2005, Critical reviews in toxicology.
[24] D. Hicklin,et al. Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.
[25] R. Moats,et al. In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.
[26] B. Teicher,et al. Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multicellular Resistance to Alkylating Agents , 2004, Molecular and Cellular Biology.
[27] C. Rüegg,et al. Manganese-induced integrin affinity maturation promotes recruitment of αVβ3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src , 2004, Thrombosis and Haemostasis.
[28] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[29] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[30] A. Richmond,et al. Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. , 2004, Molecular biology of the cell.
[31] G. Gillespie,et al. Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents , 2004, Journal of Neuro-Oncology.
[32] Michael S. Pepper,et al. αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro , 2004, Angiogenesis.
[33] A. Reynolds,et al. Integrins in angiogenesis: multitalented molecules in a balancing act , 2003, Cell and Tissue Research.
[34] G. Tucker. Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.
[35] J. Verweij,et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .
[36] J. Gratton,et al. Vascular Endothelial Growth Factor-dependent Down-regulation of Flk-1/KDR Involves Cbl-mediated Ubiquitination CONSEQUENCES ON NITRIC OXIDE PRODUCTION FROM ENDOTHELIAL CELLS* , 2003 .
[37] S. Goodman,et al. alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. , 2003, Angiogenesis.
[38] Arnoud Sonnenberg,et al. The fibronectin-binding integrins α5β1 and αvβ3 differentially modulate RhoA–GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis , 2002, The Journal of cell biology.
[39] G. Tucker,et al. Substituted benzocyloheptenes as potent and selective αv integrin antagonists , 2002 .
[40] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[41] R. Hynes. A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.
[42] K. Weinberg,et al. αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin , 2002, International journal of cancer.
[43] K. Messmer,et al. Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo , 2002, British Journal of Cancer.
[44] D. Taverna,et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.
[45] M. Roberts,et al. PDGF-regulated rab4-dependent recycling of αvβ3 integrin from early endosomes is necessary for cell adhesion and spreading , 2001, Current Biology.
[46] M. Pfaffl,et al. A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.
[47] F. Ross,et al. Superactivation of integrin (α)v(β)3 by low antagonist concentrations , 2001 .
[48] F. Ross,et al. Superactivation of integrin alphavbeta3 by low antagonist concentrations. , 2001, Journal of cell science.
[49] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[50] Hiroyuki Shimada,et al. Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.
[51] M. Roberts,et al. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. , 2001, Current biology : CB.
[52] J. Segall,et al. Epidermal growth factor receptor distribution during chemotactic responses. , 2000, Molecular biology of the cell.
[53] F. Mitjans,et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .
[54] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.
[55] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[56] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] M. Bretscher. Moving Membrane up to the Front of Migrating Cells , 1996, Cell.
[58] F. Sarkar,et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.
[59] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[60] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[61] D. Gale. Molecular targets in cancer therapy. , 2003, Seminars in oncology nursing.
[62] D. Gale. MOLECULAR TARGETS FOR CANCER THERAPY , 1990, The Lancet.